Corvus Pharmaceuticals announced on December 4, 2024, the publication of preclinical data for soquelitinib in npj Drug Discovery, a Nature portfolio journal. The publication, titled 'Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity,' details the drug's mechanism of action.
The published data demonstrates that soquelitinib suppresses Th2 and Th17 cytokine production while preserving Th1 cytokines, offering a novel approach to cancer immunotherapy. It also shows that soquelitinib enhances the effector function of cytotoxic CD8 positive T cells and increases memory T cells with improved effector function.
This scientific validation reinforces the unique potential of soquelitinib and ITK inhibition as a therapy that modulates parallel signaling pathways in the immune system. The findings support its ongoing clinical development for peripheral T cell lymphoma and atopic dermatitis, as well as broader opportunities in oncology and immune diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.